aDepartment of Medical Oncology, Leiden University Medical Center
bDutch Institute for Clinical Auditing, Leiden
cDepartment of Health Technology Assessment, Erasmus School of Health Policy & Management
dInstitute for Medical Technology Assessment, Erasmus University Rotterdam
eDepartment for Medical Oncology, Erasmus MC Cancer Institute, Rotterdam
fDepartment of Medical Oncology, Maastricht University Medical Center, Maastricht
Departments of gSurgical Oncology
hMedical Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital
iDepartment of Medical Oncology, VU University Medical Center, Amsterdam
jDepartment of Internal Medicine, Zuyderland Medical Center Geleen, Heerlen
kDepartment of Medical Oncology, University Medical Center Utrecht
lNetherlands Comprehensive Cancer Organisation, Utrecht
mDepartment of Medical Oncology, Isala, Zwolle
nDepartment of Medical Oncology, University Medical Center Groningen, Groningen
oDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen
pDepartment of Internal Medicine, Medical Spectrum Twente, Enschede
qDepartment of Internal Medicine, Medical Center Leeuwarden, Leeuwarden
rDepartment of Internal Medicine, Amphia Hospital, Breda
sDepartment of Internal Medicine, Maxima Medical Center, Veldhoven, The Netherlands
*Anouk Jochems and Brenda Leeneman contributed equally to the writing of this article.
Correspondence to Anouk Jochems, MD, MSc, Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, PO Box 9600, 2300 RC Leiden, The Netherlands Tel: +31 71 5263486; fax: +31 71 5264036; e-mail: [email protected]
Received October 5, 2017
Accepted March 15, 2018
